Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment [Phase 3]
Phase 3 clinical trial update: imetelstat is being studied versus best available therapy in intermediate-2 or high-risk myelofibrosis patien…
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Momelotinib Effectiveness in Myelofibrosis
This clinical trial update reports on the use of momelotinib for myelofibrosis, with the study currently not recruiting.
-
CLINICAL_TRIALS other · 2025-11-18Clinical Trial Update: Managed Access Programs for INC424, Ruxolitinib
Novartis-sponsored update on managed access programs for INC424 (ruxolitinib), outlining eligible indications including primary myelofibrosi…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis [Phase 1]
Phase 1 clinical trial evaluating the combination of ruxolitinib and abemaciclib for myelofibrosis (including myelofibrosis associated with …
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: P1101 in Treating Patients With Myelofibrosis [Phase 2]
A Phase 2 trial of P1101 for primary and secondary myelofibrosis has been terminated. Results from the trial were posted on 2025-10-27.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describes fedratinib in Japanese patients with DIPSS-intermediate/high-risk primary myelofibrosis, post-po…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. …
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis [Phase 2]
A Phase 2 study evaluating single-agent selinexor versus physician's choice in participants with previously treated myelofibrosis; the trial…
-
FDA approval · 2025-10-01FDA Approved: VONJO — Supplemental Application (Sobi, Inc.)
The FDA approved a supplemental application for VONJO (pacritinib) from Sobi, Inc., expanding its labeling for the treatment of adults with …
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative [Phase 1, Phase 2]
This clinical trial update reports safety findings from Phase 1/2 studies of Flonoltinib Maleate Tablets in patients with myeloproliferative…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib [Phase 3]
Phase 3 trial evaluating navtemadlin added to ruxolitinib in JAK inhibitor-naïve myelofibrosis patients with suboptimal response; currently …
-
CLINICAL_TRIALS other · 2025-09-23Clinical Trial Update: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis [Phase 2]
This document provides a clinical trial update on RVU120 in patients with intermediate- or high-risk primary or secondary myelofibrosis, cur…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) [Phase 2]
Extension-phase update for bomedemstat (IMG-7289/MK-3543) in myeloproliferative neoplasms. The Phase 2 extension study in essential thromboc…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating BMS-986158 alone and in combination with ruxolitinib or fedratinib in patients with myelofibrosis; the study…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis [Phase 2]
Phase 2 trial results report long-term safety and side effects of ruxolitinib in patients with myelofibrosis.
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients [Phase 1]
Phase 1 study of TQ05105 tablet for myelofibrosis in patients resistant or intolerant to ruxolitinib has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects [Phase 1]
Phase 1 trial evaluating the pharmacokinetics and safety of TQ05105 tablets in renal-impairment subjects with myelofibrosis; the study has c…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
This update reports on a completed Phase 1/2 study evaluating the safety, pharmacokinetics, pharmacodynamics, and dose expansion of PXS-5505…
-
FDA approval · 2025-08-22FDA Approved: VONJO — Supplemental Application (Sobi, Inc.)
FDA approved a Supplemental Application for Vonjo (pacritinib) from Sobi, Inc., updating the product labeling.
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: A Study of GLB-001 in Patients With Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial evaluating GLB-001 in patients with myeloid malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Quantitative MRI for Myelofibrosis
A clinical trial at the University of Michigan Rogel Cancer Center is exploring quantitative MRI for myelofibrosis and is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2025-08-13Clinical Trial Update: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk [Phase 3]
A Phase 3 clinical trial evaluating P1101 in patients with early or overt primary myelofibrosis at low or intermediate-1 risk is currently r…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients [Phase 1, Phase 2]
A platform phase 1/2 study evaluating novel ruxolitinib combinations in myelofibrosis has been terminated; results from the study have been …
-
CLINICAL_TRIALS trial_result · 2025-07-29Clinical Trial Update: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. [Phase 2]
A Phase 2 clinical trial conducted at Massachusetts General Hospital evaluated ruxolitinib given before, during, and after allogeneic stem c…